Targeting HSP90 in Gynecologic Cancer: Molecular Mechanisms and Therapeutic Approaches

Overview

Journal Cell Biochem Biophys

Specialties Biochemistry
Biophysics
Cell Biology

Date 2024 Sep 9

PMID 39249180

Authors

Lu Min

Xuewei Li

Lily Liang

Zheng Ruan

Shaohui Yu

Affiliations

Soon will be listed here.

Abstract

One of the leading causes of mortality for women is gynecologic cancer (GC). Numerous molecules (tumor suppressor genes or oncogenes) are involved in this form of cancer's invasion, metastasis, tumorigenic process, and therapy resistance. Currently, there is a shortage of efficient methods to eliminate these diseases, hence it is crucial to carry out more extensive studies on GCs. Novel pharmaceuticals are required to surmount this predicament. Highly conserved molecular chaperon, heat shock protein (HSP) 90, is essential for the maturation of recently produced polypeptides and offers a refuge for misfolding or denatured proteins to be turned around. In cancer, the client proteins of HSP90 play a role in the entire process of oncogenesis, which is linked to all the characteristic features of cancer. In this study, we explore the various functions of HSPs in GC progression. We also discuss their potential as promising targets for pharmacological therapy.

Citing Articles

Advances in the structures, mechanisms and targeting of molecular chaperones.

Gu J, He Y, He C, Zhang Q, Huang Q, Bai S Signal Transduct Target Ther. 2025; 10(1):84.

PMID: 40069202 PMC: 11897415. DOI: 10.1038/s41392-025-02166-2.

References

Wang Q, Peng H, Qi X, Wu M, Zhao X . Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence. Signal Transduct Target Ther. 2020; 5(1):137. PMC: 7391668. DOI: 10.1038/s41392-020-0199-6. View

Li S, Shen H, Wan Q, Chen P, Shu C, Wang H . Downregulation of HS6ST2 Inhibits Cervical Cancer Cell Migration and Invasion and . Discov Med. 2023; 35(179):1147-1159. DOI: 10.24976/Discov.Med.202335179.111. View

Zhao C, Tang X, Chen X, Jiang Z . Multifaceted Carbonized Metal-Organic Frameworks Synergize with Immune Checkpoint Inhibitors for Precision and Augmented Cuproptosis Cancer Therapy. ACS Nano. 2024; 18(27):17852-17868. DOI: 10.1021/acsnano.4c04022. View

Keyvani V, Riahi E, Yousefi M, Esmaeili S, Shafabakhsh R, Hasan-Abad A . Gynecologic Cancer, Cancer Stem Cells, and Possible Targeted Therapies. Front Pharmacol. 2022; 13:823572. PMC: 8888850. DOI: 10.3389/fphar.2022.823572. View

Wei H, Zhang Y, Jia Y, Chen X, Niu T, Chatterjee A . Heat shock protein 90: biological functions, diseases, and therapeutic targets. MedComm (2020). 2024; 5(2):e470. PMC: 10811298. DOI: 10.1002/mco2.470. View

Sager R, Khan F, Toneatto L, Votra S, Backe S, Woodford M . Targeting extracellular Hsp90: A unique frontier against cancer. Front Mol Biosci. 2022; 9:982593. PMC: 9428293. DOI: 10.3389/fmolb.2022.982593. View

Yang Y, Zhang M, Wang Y . The roles of histone modifications in tumorigenesis and associated inhibitors in cancer therapy. J Natl Cancer Cent. 2024; 2(4):277-290. PMC: 11256729. DOI: 10.1016/j.jncc.2022.09.002. View

Li Z, Luo Y . HSP90 inhibitors and cancer: Prospects for use in targeted therapies (Review). Oncol Rep. 2022; 49(1). PMC: 9685368. DOI: 10.3892/or.2022.8443. View

Hu C, Yang J, Qi Z, Wu H, Wang B, Zou F . Heat shock proteins: Biological functions, pathological roles, and therapeutic opportunities. MedComm (2020). 2022; 3(3):e161. PMC: 9345296. DOI: 10.1002/mco2.161. View

10.

Backe S, Sager R, Regan B, Sit J, Major L, Bratslavsky G . A specialized Hsp90 co-chaperone network regulates steroid hormone receptor response to ligand. Cell Rep. 2022; 40(2):111039. PMC: 9306012. DOI: 10.1016/j.celrep.2022.111039. View

11.

Niinuma S, Lubbad L, Lubbad W, Moin A, Butler A . The Role of Heat Shock Proteins in the Pathogenesis of Polycystic Ovarian Syndrome: A Review of the Literature. Int J Mol Sci. 2023; 24(3). PMC: 9915177. DOI: 10.3390/ijms24031838. View

12.

Wang Q, Tang X, Lv X, Meng X, Geng L, Zhong Z . Age at menarche and risk of ovarian hyperstimulation syndrome in women undergoing IVF/ICSI cycles: a retrospective cohort study. BMJ Open. 2024; 14(2):e076867. PMC: 10875511. DOI: 10.1136/bmjopen-2023-076867. View

13.

Velazquez M, Alfaro N, Salvetti N, Stangaferro M, Rey F, Panzani C . Levels of heat shock protein transcripts in normal follicles and ovarian follicular cysts. Reprod Biol. 2011; 11(3):276-83. DOI: 10.1016/s1642-431x(12)60072-2. View

14.

Hoter A, El-Sabban M, Naim H . The HSP90 Family: Structure, Regulation, Function, and Implications in Health and Disease. Int J Mol Sci. 2018; 19(9). PMC: 6164434. DOI: 10.3390/ijms19092560. View

15.

Prodromou C, Bjorklund D . Advances towards Understanding the Mechanism of Action of the Hsp90 Complex. Biomolecules. 2022; 12(5). PMC: 9138868. DOI: 10.3390/biom12050600. View

16.

Biebl M, Buchner J . Structure, Function, and Regulation of the Hsp90 Machinery. Cold Spring Harb Perspect Biol. 2019; 11(9). PMC: 6719599. DOI: 10.1101/cshperspect.a034017. View

17.

Isobe N, Yoshimura Y . Deficient proliferation and apoptosis in the granulosa and theca interna cells of the bovine cystic follicle. J Reprod Dev. 2007; 53(5):1119-24. DOI: 10.1262/jrd.19041. View

18.

Velazquez M, Alfaro N, Dupuy C, Salvetti N, Rey F, Ortega H . Heat shock protein patterns in the bovine ovary and relation with cystic ovarian disease. Anim Reprod Sci. 2009; 118(2-4):201-9. DOI: 10.1016/j.anireprosci.2009.08.010. View

19.

Juliani C, Silva-Zacarin E, Santos D, Boer P . Effects of atrazine on female Wistar rats: morphological alterations in ovarian follicles and immunocytochemical labeling of 90 kDa heat shock protein. Micron. 2007; 39(5):607-16. DOI: 10.1016/j.micron.2007.04.006. View

20.

Park E, Cockrem J, Han K, Kim D, Jung M, Chu J . Stress-induced activation of ovarian heat shock protein 90 in a rat model of polycystic ovary syndrome. J Obstet Gynaecol Res. 2011; 38(2):396-407. DOI: 10.1111/j.1447-0756.2011.01705.x. View